Mindray, iMDsoft Join Forces - Analyst Blog

Leading Chinese medical devices maker Mindray Medical International Limited (MR) has inked a distribution pact with Massachusetts-based leading clinical information systems provider iMDsoft. Under the pact, Mindray will be the exclusive distributor of iMDsoft's MetaVision clinical information systems in China. Moreover, the company will market MetaVision Suite solutions in 10 countries across Europe, Africa and Asia.

The partnership is a strategic fit for Mindray enabling it to offer a comprehensive suite of MetaVision solutions across mainland China and international markets. The MetaVision Suite has been designed to collect, analyze, report and store vast amounts of patient-related data generated in critical care environments. The solution has been adopted by hospitals, healthcare systems and major medical centers across the globe to promote patient safety, contain costs and support research and compliance.

The MetaVision Suite, which has a proven track record across 20 countries globally, leverages a single platform to automate workflows in a range of clinical environments including intensive care, pre-operative, post-operative and general in-patient beds.It seamlessly interoperates with a vast continuum of medical devices and hospital information systems.

With its operational headquarters in Shenzhen, China, Mindray is a global Chinese medical devices company. It operates through three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products and Medical Imaging Systems. The company's products hold a roughly 40% share of the Chinese healthcare market.

Besides China, Mindray operates in North America, Europe and other Asian countries.  The company competes with global devices manufacturers such as General Electric (GE), Philips (PHG) and Siemens (SI).

Mindray has a strong position in the low and mid segments of the medical devices market in China and is poised to benefit from the solid fundamentals of the Chinese health care sector. Its new product development initiatives, expanding international footprint (and revenues) and solid sales infrastructure remain encouraging.

Although Mindray's strength is currently in the low and mid-end segments, the companyis looking to carve a niche in the high-end markets. Moreover, Mindray is well positioned to benefit from the health care reforms in China.However, the company is exposed to intense competition-driven pricing pressure.   

 
GENL ELECTRIC (GE): Free Stock Analysis Report
 
MINDRAY MEDICAL (MR): Free Stock Analysis Report
 
KONINKLIJKE PHL (PHG): Free Stock Analysis Report
 
SIEMENS AG-ADR (SI): Free Stock Analysis Report
 
Zacks Investment Research